BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32651889)

  • 1. Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service.
    Zekery-Saad SA; Lewin A; Pham M; Sylvester KW; Fanikos J; Goldhaber SZ; Connors JM
    J Thromb Thrombolysis; 2021 Feb; 51(2):405-412. PubMed ID: 32651889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
    Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
    Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
    Liao YWB; Wang TKM
    Coron Artery Dis; 2020 May; 31(3):260-265. PubMed ID: 31821195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
    Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH;
    Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database.
    Tanaka J; Koseki T; Sekido K; Kimata M; Ito Y; Yamada S
    J Pharm Pharm Sci; 2023; 26():11263. PubMed ID: 37122387
    [No Abstract]   [Full Text] [Related]  

  • 7. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
    Schwalm JD; Ahmad M; Salehian O; Eikelboom JW; Natarajan MK
    J Thromb Thrombolysis; 2010 Aug; 30(2):127-32. PubMed ID: 20157843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP; Bhatt DL; Oldgren J; Lip GYH; Ellis SG; Kimura T; Maeng M; Merkely B; Zeymer U; Gropper S; Nordaby M; Kleine E; Harper R; Manassie J; Januzzi JL; Ten Berg JM; Steg PG; Hohnloser SH;
    N Engl J Med; 2017 Oct; 377(16):1513-1524. PubMed ID: 28844193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
    Orford JL; Fasseas P; Melby S; Burger K; Steinhubl SR; Holmes DR; Berger PB
    Am Heart J; 2004 Mar; 147(3):463-7. PubMed ID: 14999195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes associated with combined antiplatelet and anticoagulant therapy.
    Johnson SG; Rogers K; Delate T; Witt DM
    Chest; 2008 Apr; 133(4):948-54. PubMed ID: 18198244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).
    Ten Berg JM; Steg PG; Bhatt DL; Hohnloser SH; de Veer A; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Cannon CP;
    Am J Cardiol; 2020 Mar; 125(5):735-743. PubMed ID: 31924322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
    Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic regimens in patients with indication for long-term anticoagulation undergoing coronary interventions-systematic analysis, review of literature, and implications on management.
    Deshmukh A; Hilleman DE; Del Core M; Nair CK
    Am J Ther; 2013; 20(6):654-63. PubMed ID: 21519218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
    Almarzooq ZI; Al-Roub NM; Kinlay S
    Curr Opin Cardiol; 2023 Nov; 38(6):515-520. PubMed ID: 37522805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment.
    Zhao HJ; Zheng ZT; Wang ZH; Li SH; Zhang Y; Zhong M; Zhang W
    Chest; 2011 Feb; 139(2):260-270. PubMed ID: 21285053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
    Khurram Z; Chou E; Minutello R; Bergman G; Parikh M; Naidu S; Wong SC; Hong MK
    J Invasive Cardiol; 2006 Apr; 18(4):162-4. PubMed ID: 16729401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
    Huber K; Bates ER; Valgimigli M; Wallentin L; Kristensen SD; Anderson JL; Lopez Sendon JL; Tubaro M; Granger CB; Bode C; Ohman EM; Steg PG
    Am Heart J; 2014 Nov; 168(5):611-21. PubMed ID: 25440788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.